The inactivation of the p53 tumor suppressor pathway in many cancers often increases their resistance to anticancer therapy. Here we show that a previously proposed strategy directed to Wip1 inhibition could be ineffective in tumors lacking p53. On the contrary, Wip1 overexpression sensitized these tumors to chemotherapeutic agents. This effect was mediated through interaction between Wip1 and RUNX2 that resulted, in response to anticancer treatment, in RUNX2-dependent transcriptional induction of the proapoptotic Bax protein. The potentiating effects of Wip1 overexpression on chemotherapeutic agents were directed only to tumor cells lacking p53. The overexpression of Wip1 in normal tissues provided protection from cisplatin-induced apoptosis through decreased strength of upstream signaling to p53. Thus, Wip1 phosphatase promotes apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents.
The inactivation of the p53 tumor suppressor pathway in many cancers often increases their resistance to anticancer therapy. Here we show that a previously proposed strategy directed to Wip1 inhibition could be ineffective in tumors lacking p53. On the contrary, Wip1 overexpression sensitized these tumors to chemotherapeutic agents. This effect was mediated through interaction between Wip1 and RUNX2 that resulted, in response to anticancer treatment, in RUNX2-dependent transcriptional induction of the proapoptotic Bax protein. The potentiating effects of Wip1 overexpression on chemotherapeutic agents were directed only to tumor cells lacking p53. The overexpression of Wip1 in normal tissues provided protection from cisplatin-induced apoptosis through decreased strength of upstream signaling to p53. Thus, Wip1 phosphatase promotes apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents.
caspases | Bcl-2 family | dephosphorylation | intestine T he tumor suppressor p53 is a transcriptional factor that is activated by various stresses and initiates cell cycle arrest, DNA repair, and apoptosis (1) . The importance of p53 in suppressing tumor initiation and growth is indicated by the fact that more than half of all human cancers lose p53 function through mutation or depletion of the p53 gene (2) . The consequences of p53 loss are multiple; not only does it influence growth, genomic stability, and other tumor characteristics, but it also affects the efficacy of anticancer treatment.
Alternatively, tumor cells could use negative regulators of p53 to suppress its activity. For example, a significant number of human cancers exhibit Mdm2 gene amplification and/or overexpression (3) . Mdm2 gene encodes an E3 ubiquitin ligase that interacts with p53 and mediates p53 proteasomal degradation. P53 activates Mdm2 expression, forming a negative feedback regulatory loop (4, 5) .
Another feedback mechanism in the p53 pathway is connected to its posttranslational modification. After stress, p53 undergoes various posttranslational modifications that increase p53 stability and/or potentiate its transcriptional activity (6) . Among the genes whose expression is regulated by p53 is the PP2C serine-threonine phosphatase Wip1 (gene name PPM1D). Similarly to Mdm2, the Wip1 gene (PPM1D) is amplified in many tumor types (7, 8) . Wip1 overexpression leads to dephosphorylation of crucial activating phosphoserines or phosphothreonines found in the DNA damage response protein kinases ATM, Chk2, and Chk1, among others. DNA damage response kinases are important transducers of signals from damaged DNA to p53. The inhibition of the ATM/Chk2 kinase cascade by Wip1 prevents p53 activation (9) (10) (11) . Additionally, it was shown that phospho-Ser15 in p53, which is important for p53 activity, could be directly dephosphorylated by Wip1 (12) . Wip1-KO mice exhibit a tumor-suppressive phenotype in several cancer models such as lymphomagenesis and mammary gland or intestinal tumorigenesis (13) (14) (15) (16) . Therefore, Wip1 inhibition may have clinical implications given the potential therapeutic uses of compounds that interfere with Wip1 suppression of p53 activity. Indeed, expression of a Wip1 antisense transcript in the breast carcinoma cell line MCF-7 resulted in increased p53-dependent apoptosis (17) . Several studies in mice have shown that the tumorsuppressive phenotype of Wip1 deletion_is p53-dependent and that p53 loss completely reverses the effect in these systems. Thus, Wip1 inhibition is probably only effective in tumors with preserved WT p53.
Currently, the majority of anticancer therapies use the p53 pathway to induce tumor cells death (18) . Following activation by anticancer drugs, p53 induces the expression of numerous genes, including proapoptotic genes such as Bax (19) . Elevated expression of proapoptotic genes leads to initiation of the apoptotic program and eventually to cell death. In contrast, tumors bearing mutant p53 often exhibit resistance to anticancer drugs (20, 21) . Effective therapy of tumors with inactive p53 continues to present a challenge for modern oncology. To overcome this issue, several strategies have been proposed. For example, inactivation of Chk1 kinase in p53-negative tumors compromises G2 arrest in response to anticancer therapy and induces mitotic catastrophe, eliminating tumor cells (22) . Unfortunately, Chk1 inhibition could be highly toxic to normal tissues and may induce severe side effects (23) .
Here we report an alternative approach, based on activation of Wip1 phosphatase, toward sensitizing tumors containing inactive p53 to anticancer drugs, while at the same time protecting normal tissues. In response to anticancer drugs in tumors with inactive p53, Wip1 overexpression led to the induction of Bax through dephosphorylation-dependent activation of the transcription factor RUNX2. In normal tissues, Wip1 suppressed p53 hyperactivation in response to anticancer therapy, thereby decreasing normal tissue damage. Thus, in tumors lacking functional p53, Wip1 acts as a sensitization factor to anticancer drugs while protecting normal tissues bearing WT p53 from side effects of anticancer therapies.
Results

Wip1 Overexpression Increases Sensitivity of Tumor Cells with
Inactive p53 to Anticancer Drugs. Wip1 inhibition was proposed as a novel anticancer strategy directed to nongenotoxic activation of p53 (24) . At the same time, in several mouse models of tumorigenesis, the tumor-resistant phenotype of Wip1-null mice was abrogated by p53 deletion, supporting the interpretation that effects of Wip1 deletion are mediated through the p53 pathway (15) . The p53 tumor suppressor mutated or lost in approximately 50% of human tumors. Therefore, the status of p53 may affect the response of tumor cells to Wip1 inhibition. First, we analyzed the effect of Wip1 depletion on the sensitivity to an anticancer agent of several tumor cell lines with or without p53. As expected, Wip1 depletion (Fig. S1A ) increased sensitivity to cisplatin (i.e., CDDP) in tumor cell lines expressing WT p53, the osteosarcoma cell line U2OS and the colon cancer cell line HCT116, but it had no effect on the sensitivity in HCT116 p53 −/− or the p53-negative osteosarcoma cell line Saos-2 (Fig. 1A) .
To examine the effect of Wip1 overexpression on the sensitivity of tumor cells to anticancer drugs, we generated two human cell lines, U2OS-Wip1-on (WT p53) and Saos-2-Wip1-on (p53 deletion), in which Wip1 expression was regulated by a tetracycline inducible promoter (Fig. S1B) . Induction of Wip1 in the cells with WT p53 mildly protected the cells from anticancer treatment with cisplatin. In sharp contrast, in the highly cisplatin-resistant, p53-negative Saos-2 cells, previous Wip1 induction strongly increased Saos-2-Wip1-on cell death in response to cisplatin (Fig. 1B and  Fig. S1C ). Interestingly, Wip1 overexpression in Saos-2-Wip1-on cells increased cell death only after cisplatin treatment. Wip1 induction had no effect on survival of nontreated Saos-2-Wip1-on cells. Thus, Wip1 overexpression sensitized Saos-2 cells to cisplatin-induced cell death, but did not induce cell death by itself. ) to cisplatin. Cells were infected with retrovirus expressing Wip1 and treated with 25 μM CDDP for 48 h, harvested, and subjected to Guava ViaCount cell death assay (*P < 0.05, **P < 0.01, and ***P < 0.001; ns, not statistically significant at the 95% confidence level). Data represent the mean ± SEM of two to four independent experiments.
To address the involvement of Wip1 phosphatase activity in the observed sensitization phenotype, we established the stably transfected Saos-2-Wip1 D314A-on cell line, which features inducible Wip1 bearing the phosphatase activity-impaired D314A mutation (Fig. S1D) (25) . As shown in Fig. 1C , the D314A mutation in the phosphatase domain of Wip1 abrogated the Wip1-dependent sensitization. Thus, we concluded that the observed sensitization in Saos-2-Wip1-on cells depended on the phosphatase activity of Wip1.
To demonstrate that the sensitization was not specific only to cisplatin, we extended the panel of anticancer agents by treating Saos-2 cells with etoposide, 5-fluorouracil, and camptothecin. We observed that Wip1 overexpression significantly (P < 0.05) increased cell death induced by etoposide, 5-fluorouracil, or camptothecin in Saos-2-Wip1-on cells (Fig. 1D) , similar to the induction of cell death by these drugs in WT p53 cells, U2OS (Fig. S1G ).
To address whether this effect was specific for the osteosarcoma-derived Saos-2 cells or was applicable more broadly to other p53-negative cells, we generated an H1299 Tet-inducible Wip1 cell line (Fig. S1E) ; the H1299 cell line was derived from human nonsmall cell lung carcinoma and is null for p53 (26) . Overexpression of Wip1 in H1299 cells potentiated cell death induced by cisplatin in a similar way as was observed in the Saos-2 cell line (Fig. 1E ). Furthermore, a sensitization to anticancer drugs was also observed after retroviral overexpression of Wip1 ( These results indicate that activation of Wip1 may potentiate the efficiency of anticancer drugs in tumors lacking p53. We decided next to explore the potential mechanism of this effect.
G2 Checkpoint in p53-Negative Cells Is Unaffected by Wip1 Over expression. Previously, Wip1 has been characterized as a negative regulator of Chk1 kinase (12) . Furthermore, our earlier studies of p53-negative tumors, which have defective checkpoints, showed that inhibition of Chk1 sensitized the tumors to anticancer treatments through abrogation of the G2 checkpoint, resulting in premature mitosis entrance with unrepaired DNA and subsequent mitotic catastrophe (22) . Therefore, we examined whether Wip1 overexpression affected Chk1 activation in response to cisplatin treatment. We observed only a slight delay in the phosphorylation of the Chk1 activating sites Ser317 and Ser345 in response to cisplatin treatment in Saos-2 cells after Wip1 induction ( Fig. 2A) . We analyzed whether Saos-2-Wip1-on cells could bypass G2 checkpoint during cisplatin treatment. We determined the fraction of cells in mitotic phase, using phosphorylated histone H3 as a mitotic marker. Cisplatin treatment resulted in fewer mitotic phase cells, indicating an effective G2 checkpoint in Saos-2-Wip1-on cells, either with or without Wip1 overexpression (Fig. 2B) .
Thus, it is unlikely that inhibition of Chk1, with ensuing compromised G2 arrest and mitotic catastrophe, is responsible for sensitization resulting from Wip1 overexpression through compromised G2 arrest and mitotic catastrophe.
Wip1 Overexpression Permits Apoptosis in Response to Anticancer
Drugs in Tumor Cells Lacking p53. Next we investigated the mechanism of enhanced cell death resulting from Wip1 overexpressioninduced sensitization to anticancer treatment. We noted that Saos-2-Wip1-on cells displayed the typical apoptotic morphology after treatment with anticancer drugs only when also treated with doxycycline, which induced Wip1 overexpression. To investigate the mechanism of increased apoptosis in greater detail, we determined the levels of several proapoptotic proteins. As expected, in U2OS cells, which contain functional p53, cisplatin treatment induced activation of caspases (caspases 3 and 9) irrespective of the presence or absence of Wip1 overexpression (Fig. 3A) . In contrast, cisplatin treatment of Saos-2 cells, which lack functional p53, did not induce caspase activation. We observed elevated levels of active caspase-3 and caspase-9 after cisplatin treatment only in Saos-2 cells with induced Wip1 (Fig. 3B) . To investigate further the mechanism of increased apoptosis, we examined the levels of selected pro-and antiapoptotic proteins. As shown in Fig.  3C , cisplatin treatment strongly induced Bax protein levels in Saos-2 cells overexpressing Wip1 whereas Bax protein levels remained unchanged in the absence of Wip1 induction, thus correlating with caspase activation. The antiapoptotic Bcl-2 protein levels in these cells were not strongly affected by cisplatin treatment in the absence or presence of Wip1 induction (Fig. 3C) . The proapoptotic proteins Bad and Puma did not increase in response to cisplatin treatment either in the absence or presence of Wip1 induction, although the level of Puma decreased at the later time in the presence of Wip1 overexpression (Fig. S2A) . Interestingly, the level of the antiapoptotic Bcl-xl protein increased following cisplatin treatment in the absence of Wip1 induction, but remained low in cells overexpressing Wip1 following cisplatin treatment (Fig. S2A) . Thus, when Wip1 is overexpressed, cisplatin treatment results in increased levels of Bax and reduced levels of Bcl-xl.
The ratio of Bax to Bcl-xl is a critical determinant in the induction of apoptosis. In cells with WT p53, Bax induction in response to anticancer therapy is mediated through the binding of p53 to a specific response element in the Bax promoter, resulting in increased Bax transcription. Saos-2 cells bear a deletion in the p53 gene that prevents p53 expression (27) . As expected, p53 protein was not detected in Saos-2 or Saos-2-Wip1-on cells under any condition, whereas cisplatin treatment of U2OS-Wip1-on cells resulted in strong or attenuated increases in the level of p53 in the absence or presence of Wip1 induction, respectively (Fig. S2B) .
Therefore, p53 could not be responsible for the increased transcription of Bax in Wip1-overexpressing Saos-2 cells after cisplatin treatment. We concentrated our further efforts on understanding the mechanism of Bax up-regulation as a major trigger of apoptosis in response to cisplatin in the absence of functional p53.
Apoptosis Induced by Cisplatin and Wip1 Overexpression Is RUNX2-Dependent. Among other possible transcriptional activators of Bax is RUNX2, a transcription factor involved in osteoblast differentiation that also has been implicated in the development of breast and prostate cancers (28, 29) . RUNX2 has been identified as an inducer of Bax expression in response to TGF signaling, and two RUNX2 binding elements have been identified in the Bax promoter (30) . By treating cells with RUNX2 siRNA, we abrogated the Wip1-dependent sensitization of Saos-2 cells to cisplatin, as demonstrated by the inhibition of apoptosis (Fig. 4A and Fig.  S3A ). Furthermore, we observed that Wip1 induction resulted in an increase in Bax mRNA levels in cells treated with control siRNA, but observed no increase in Bax mRNA levels in the RUNX2-depleted cells (Fig. 4B ).
Wip1 Interacts with RUNX2 and Activates Its Transcriptional Activity
Through Dephosphorylation of Ser432. We performed coimmunoprecipitation experiments and found that Wip1 interacted with RUNX2 in Saos-2-Wip1-on cells (Fig. 4C) and also in HCT116 p53 −/− and HT29 cells (Fig. S3B) . We analyzed the sequence of RUNX2 and found several potential sites of serine phosphorylation residing in amino acid contexts similar to those of previously characterized Wip1 phosphatase substrates. We separately mu-
the regulation of Bax-promoter including the Runx binding sites and either WT or mutated RUNX2 expression plasmids. Expression of WT RUNX2 induced luciferase activity more than threefold compared with the empty vector (Fig. S3C) . Mutation of RUNX2 Ser432 to alanine resulted in significantly increased transcriptional activity of the Bax promoter, compared with WT RUNX2 (Fig. 4D) . The S430A mutation resulted in increased luciferase activity, but the difference was not significant at the 95% confidence level. The mutations S283A and S516A did not significantly affect RUNX2-induced luciferase expression.
To confirm that phospho-Ser432 of RUNX2 was a target for Wip1, we synthesized human RUNX2 peptide containing phosphorylated Ser432 and measured the peptide concentration dependence of Wip1 phosphatase activity. As shown in Fig. 4E , the results displayed Michaelis-Menten kinetics with a K m of 136 μM and a V max of 0.039 pmol/ng/s. These kinetic constants were similar to those obtained with the Chk1 345pS phosphopeptide, a well known substrate for Wip1 (12) . It was reported that Runx2 activity was negatively regulated by phosphorylation of Ser465, an SP site (31, 32) . As expected, Wip1 did not show measurable activity against the Runx2 phospho Ser465 peptide. The ATM-1981pS peptide, an established substrate for Wip1, was used as a positive control; the kinetic constants determined (K m = 30 μM, V max = 0.010 pmol/ng/s) were very similar to those previously reported (11) . Combined with the results of luciferase assay of S432A mutant, these data suggested that Ser432 of RUNX2 is a substrate for Wip1 phosphatase activity.
Thus, following cisplatin treatment, the interaction of Wip1 with RUNX2 and subsequent dephosphorylation of Ser432 can potentiate the transcriptional activity of RUNX2, leading to increased levels of Bax and, consequently, increased level of apoptosis.
Wip1 Overexpression Sensitizes p53-Negative Tumors to Cisplatin in
Vivo. To confirm our findings in vivo, we established Saos-2 tumors without or with doxycycline-inducible Wip1 expression explanted into athymic nude mice. Tumors were allowed to grow to a visible size (50 mm 3 ), at which time Wip1 was induced by addition of doxycycline (2 mg/mL) into the drinking water. A single i.p. injection of cisplatin (10 mg/kg) abrogated tumor growth only in tumors with Wip1 overexpression (Fig. 5A ).
Wip1 Overexpression Protects Normal Tissues from Cell Death Induced by Cisplatin. In contrast to increased apoptosis resulting from Wip1 overexpression in tumors lacking functional p53, the overexpression of Wip1 reduced cell death in tumor cells with WT p53 during treatment with anticancer drugs (Fig. 1B) . Therefore, in our proposed model, Wip1 overexpression sensitizes only tumor cells lacking functional p53. We hypothesized that normal cells, with preserved WT p53, should be protected by Wip1 down-regulation of the p53 response to anticancer drugs. We used pUbC-Wip1 transgenic mice with ubiquitous Wip1 overexpression (33) to analyze the effects of Wip1 activation in normal tissues during anticancer treatment. Among the most sensitive tissues to anticancer agents are the intestinal epithelium and the reproductive tissues. We compared cisplatin-induced apoptosis in intestinal crypts and testes of WT mice and mice with Wip1 overexpression. We observed a significant decrease in activated caspase 3-positive cells in both organs (Fig. 5 B-E) . Thus, Wip1 overexpression, while sensitizing p53 negative tumors to chemotherapy, can protect normal tissue from deleterious effects of cisplatin anticancer treatment.
Discussion
The development of more efficient strategies for cancer treatment is one of the most important tasks for modern oncology. Many therapeutic approaches under development are targeted to the status of the tumor suppressor p53 in specific tumors, whereby different strategies are engaged for WT and mutant p53 (34) . The recently proposed therapy directed toward inhibition of Wip1 phosphatase, one of the main negative regulators of the tumor suppressor protein p53, has the potential to increase the efficacy of existing anticancer therapies and prevent cancer recurrence, most particularly for tumors with WT p53 (24, 35-37) Additionally, as Wip1 is often amplified in many tumor types and its amplification or overexpression interferes with several tumor suppressor pathways (38) , the use of Wip1 inhibitors in such patients would target the tumor-specific pathogenetic mechanism.
The data presented here indicate that the p53 status in individual tumors should be determined before administration of a Wip1 inhibitor. Our data provide support to the benefit of inhibiting Wip1 in tumors with functional p53, in agreement with previous observations (17, 39) , but furthermore suggest that Wip1 inhibitors may be ineffective in tumors exhibiting loss of functional p53. In these cases, on the contrary, activation of Wip1 may potentiate the efficacy of anticancer agents, resulting in more effective treatment. Our study demonstrates that overexpression of Wip1 sensitized tumor cells to anticancer agents and that this effect required the phosphatase activity of Wip1, as overexpression of a phosphatase-impaired mutant Wip1 abrogated the sensitization of tumor cells to cisplatin. These observations motivate us to propose a search for specific Wip1 activators. Recently, chemical activators were identified for another PP2C family member, PP2Cβ (40) . Thus, the search for chemical activators of PP2Cδ -Wip1 may be rationalized in terms of potential application in cancer therapy.
Many of the recently characterized direct substrates of Wip1, including the kinases ATM, Chk1, and Chk2, as well as H2AX and p53, conform to the p-Ser/p-Thr Q motif (11, 12) . Here, we report the characterization of p-Ser432 of the transcription factor RUNX2 as a substrate of Wip1 phosphatase activity. Moreover, we observed a physical association between RUNX2 and Wip1 and demonstrated that Wip1 activates the transcriptional activity of RUNX2 through dephosphorylation of Ser432.
RUNX2 belongs to the family of RUNT-domain transcriptional factors. The Runx genes family comprises three closely related transcription factors: Runx1, Runx2, and Runx3, each of which binds a common partner, CBFβ, to form a core binding factor (CBF) complex that can activate or repress gene transcription. Runx genes are expressed in a tissue specific manner, but they have overlapping functions and the capacity for cross-regulation. The stability and activity of RUNX2 are regulated by posttranslational modifications (41, 42) . In particular, phosphorylation of RUNX2 can activate or repress its transcriptional activity (43) (44) (45) . It was proposed that some proapoptotic genes may be important carcinogenic targets of RUNX transcriptional factors and TGF-β-induced apoptosis is greatly reduced after depletion of RUNX in some tissues (46) . Recently, it was shown that RUNX2 binds to the promoter of the proapoptotic gene Bax and induces Bax expression and apoptosis in response to BMP2 stimulation and etoposide treatment in osteosarcomas Saos-2 cells (30) . In our study, Wip1 overexpression led to Bax induction and promoted caspase-dependent apoptosis in response to cisplatin treatment. This effect was abrogated by siRNA-mediated RUNX2 depletion. Moreover, substitution of the Wip1-targeted serines to alanine, which mimics dephosphorylated state, increased the transcriptional activity of RUNX2. We hypothesized that, in cells in which p53 is active, it is p53 that plays the role of the main regulator of Bax expression in response to cisplatin. The absence of active p53 caused by mutations in the p53 gene (TP53) RUNX2 can be a major transcriptional activator of Bax expression, resulting in increased Bax protein levels and increased induction of apoptosis. The ratio of Bax to Bcl-xl is critical in determining the sensitivity of cells to anticancer drugs (47) (48) (49) . Thus, we have identified RUNX2 as a target of Wip1 phosphatase activity and have shown that, during anticancer therapy, in the absence of p53, transcriptionally activated RUNX2 is responsible for mediating the increased apoptotic response.
One of the most interesting findings of our work is that the potentiating effect of increased Wip1 activity on anticancer agent treatment is restricted to tumors. Moreover, the transient activation of Wip1 may protect normal tissues from deleterious side effects of the anticancer therapy. In patients bearing tumors with a loss of functional p53 gene, the normal tissues still express WT p53, which is responsible for most of the cytotoxic effects of anticancer agents (50) . Among the organs most sensitive to this undesirable effect of anticancer therapy are the intestine and testes, leading to severe effects in the digestive and reproductive systems (51). Wip1 is highly expressed in testis and intestinal stem cells (15, 52) . Its transient activation would increase the threshold of p53 activation in response to anticancer treatment and thus prevent apoptosis. This hypothesis was supported by our observation from in vivo experiments demonstrating that, compared with WT mice, transgenic mice overexpressing Wip1 exhibited significantly less cisplatin-induced damage in the intestine and testis. In our study, we analyzed only the early, caspase 3-dependent apoptosis, which has been shown to be p53-dependent in response to DNA damage in the intestine. We propose that Wip1, as a negative regulator of p53 activity, has a maximal effect on this particular type of cell death. Other types of cell death have been implicated in the p53-dependent response to DNA-damaging treatments, and we cannot exclude the possibility that additional mechanisms are also affected by Wip1 overexpression (53) . Previously it has been shown that, although the immediate p53-dependent DNA damage response is irrelevant to the subsequent suppression of tumorigenesis, it is responsible for the severe side effects (54) . It was proposed that p53 activation is important for tumor suppression during the period following recovery from DNA damage (55) . Thus, the transient activation of Wip1 before anticancer treatments that induce the DNA damage response could suppress p53-dependent toxicity of such treatments toward normal tissues without affecting the tumor-suppressive activity of p53 pathway.
In conclusion, our study uncovers a proapoptotic function of Wip1 that acts through dephosphorylation and activation of RUNX2. We propose an anticancer strategy for the treatment of tumors that lack functional p53, which is based on the transient activation of Wip1 and simultaneously protects normal tissues.
Materials and Methods
Cell Lines and Cell Culture. The U2OS Tet-on and Saos-2 Tet-on cell lines, human osteosarcoma lines with a tetracycline-inducible gene expression system, were purchased from Clontech. To obtain cells stably expressing Wip1, the Wip1, FLAG-tagged Wip1 or FLAG-tagged Wip1 D314A mutant coding sequence was inserted in TRE2pur (Clontech). Twenty puromycin-resistant clones were isolated, amplified, and checked for inducible expression of FLAG-Wip1 protein following addition of 5 μg/mL doxycycline (D-9891; Sigma). Clonal lines with high levels of inducible Wip1 expression were used for experiments. For human non-small-cell lung cancer cell line NCI-H1299, stable clones expressing pTet-ON (Clontech) were established before transfection with the pTRE2pur-Wip1 vector. Immunohistochemistry. Tissues were fixed with 10% formalin, embedded in paraffin, and sectioned at 5 μm. Anti-caspase 3 antibody (AF835; R&D Systems) was used.
Plasmid Constructs and siRNAs. The phosphatase-inactive Wip1 point mutant D314A was described before (25) . The pCMV-RUNX2 and pGL4.10-luc-Baxpromoter vectors were a gift from Roman Eliseev (University of Rochester, Rochester, NY). To introduce point mutations into Wip1 and RUNX2, we used a QuikChange II site-directed mutagenesis kit (Stratagene).
ON-Target Anti-RUNX2 siRNA, anti-Wip1 siRNA, and control siRNA were purchased from Dharmacon (catalog nos. L-012665-00, L-004554-0005, and D-001810-01-05, respectively).
Cells were transfected with plasmid DNA by jetPEI (catalog no. 101-10; Polyplus Transfection). To transfect cells with siRNA, we used INTERFERin (catalog no. 409-10; Polyplus Transfection). Transfections experiments were performing according to manufacturer's instructions.
Wip1 cDNA was cloned into the PINCO vector (56) . Retroviral infection of HCT116 and HCT116 p53 −/− colon cancer cell lines (gifts from Bert Vogelstein, Johns Hopkins University, Baltimore, MD) were performed according to the Retroviral Gene Transfer and Expression User Manual (Clontech).
Western Blot Analysis and Immunoprecipitation. Cell lysates containing 50 μg of protein were analyzed by Western blot by using the following primary antibodies: anti-Wip1 (H-300; Santa Cruz), anti-RUNX2 (M-70; Santa Cruz), anti-p53 (DO-1; Santa Cruz ), anti-Chk1 (G-4; Santa Cruz ), anti-β-actin antibody (A 2103; Sigma), anti-phospho-Chk1 Ser345, anti-phospho-Chk1 Ser317, anti-Bax, antiBad, anti-Bcl-2, anti-Puma, anti-Bcl-xl, anti-caspase 3, and anti-caspase 9 (all from Cell Signaling Technologies). Secondary antibodies were from Jackson Immuno Research. Immunoreactivity was detected by using Western Blotting Luminol Reagent (Santa Cruz).
For immunoprecipitation, cells were seeded in 75-cm 2 flasks, treated with 5 μg/mL of doxycycline for 24 h or infected with Wip1 virus as described earlier, and lysed in Tris-buffered saline solution containing 1% Nonidet P-40, 5% glycerol, and protease inhibitors. Cell lysates were centrifuged at 15,000 × g, and supernatant was used for immunoprecipitation. Wip1-FLAG was precipitated overnight with 20 μL of Anti-FLAG M2 Affinity Gel (A2220; Sigma). RUNX2 was precipitated with 10 μg of anti-RUNX2 antibodies (M-70 X; Santa Cruz) and then 40 μL of Protein A/G beads was added to cell lysate for 4 h. Immunoprecipitates were spun down and washed three times with lysis buffer, boiled in sample buffer, and loaded on 10% SDS-polyacrylamide gels. Proteins were transferred to PVDF membrane and were detected with RUNX2 antibody (catalog no. D130-3; MBL International), anti-FLAG M2 antibody (catalog no. F1804; Sigma), and antibodies described earlier.
In Vitro Phosphatase Assay. The N-terminal histidine-tagged, catalytic domain of human Wip1 (residues 1-420), rWip1, was expressed in Escherichia coli BL21 (DE3) and purified as previously reported (57) . The sequences of the human RUNX2-432pS, RUNX2-465pS and ATM-1981pS peptides, which were synthesized by solid phase chemistry, were PYPGSSQ(pS)QSGPF, PGGDR(pS) PSRMLGY, and AFEEG(pS)QSTTIGY, respectively. Wip1 phosphatase activity was determined by measuring the released phosphate using a malachite green/molybdate based assay. For each reaction, 60 ng of rWip1 was incubated with the phosphopeptide for 7 min at 30°C in a reaction medium containing 50 mM Tris-HCl (pH 7.5), 0.1 mM EGTA, 0.02% 2-mercaptoethanol, 40 mM NaCl, and 30 mM MgCl 2 . The reaction was stopped by adding Malachite green solution (Millipore) or Biomol Green (Enzo Life Sciences), and the absorbance was measured at 650 nm or 620 nm, respectively. The data were fitted to the Michaelis-Menten equation by using GraphPad Prism 5 software.
Luciferase Assays. The luciferase reporter plasmids, pGL4.10-luc-Bax-promoter (firefly), and pRL-TK (renilla; Promega) were cotransfected along with pCMV-RUNX2 or its mutant variants into SAOS-2 cells. Firefly and renilla luciferase activities were measured by using a Lumat LB 9507 Single Tube Luminometer (Berthold Technologies) and the Dual Luciferase Reporter Assay System (Promega) according to the manufacturer's protocol. The firefly luciferase signal was normalized to the renilla luciferase signal.
Cell Death Assay. The number of dead cells was estimated by the cell death assay using the Guava ViaCount Reagent (catalog no. 4000-0041; Millipore). Cells were trypsinized, washed with PBS solution, and stained with Guava ViaCount Reagent for 5 min. The percentage of dead cells was measured by using Guava EasyCyte Plus Flow Cytometry System (Millipore) and analyzed by using Guava ViaCount Software.
Real-Time RT-PCR. Total cellular RNA was prepared using RNeasy Kit (Qiagen) and reverse-transcribed into cDNA by using SuperScript II First-Strand Synthesis Kit (Invitrogen) and oligo-dT primers according to the manufacturer's protocol. Real-time PCR was performed by using a 7500 Fast Real-Time PCR System (Applied Biosystems), KAPA SYBR FAST qPCR Kit (KAPA Biosystems), and the following sets of primers: Bax (5′-TGCTTCAGGGTTTCATCCAG-3′ and 5′-GGC-GGCAATCATCCTCTG-3′), RUNX2 (5′-CCGGAATGCCTCTGCTGTTATGA-3′ and 5′-ACTGAGGCGGTCAGAGAACAAACT-3′), and GAPDH (5′-GAAGGTGAAGG-TCGGAGTC-3′ and 5′-GAAGATGGTGATGGGATTTC-3′). The expression of mRNA of interest was normalized to the expression of GAPDH.
Statistical Analysis. Statistical analysis was performed by using GraphPad Prism 5 software. 
